Max Rosett serves as Chief Financial Officer at Immunome Inc., a clinical-stage biotechnology company developing targeted cancer therapeutics and next-generation vaccines. With over 25 years of experience in the life sciences industry, Rosett brings a proven track record of driving financial strategy and operational excellence in high-growth biotech environments. In his role at Immunome, he oversees all financial operations, including capital raising, budgeting, investor relations, and strategic partnerships, playing a pivotal role in advancing the company's innovative pipeline of immunotherapies. Prior to joining Immunome, Rosett was CFO at Kura Oncology from 2015 to 2020, where he led the company through multiple equity financings totaling over $300 million and a successful IPO on NASDAQ. Before that, he served as CFO of Aduro Biotech, guiding the firm through Phase 3 trials and key collaborations with industry leaders like Janssen. His earlier career included senior finance positions at Onyx Pharmaceuticals (acquired by Amgen) and investment banking roles at Lehman Brothers and Montgomery Securities, where he executed numerous M&A transactions and financings in the biotech sector. Rosett's achievements include optimizing capital structures to extend cash runways during critical development phases and fostering relationships that have accelerated clinical progress for multiple portfolio companies. A CPA and MBA graduate from the University of California, Berkeley, he is recognized for his strategic acumen in navigating regulatory landscapes and market volatilities, positioning Immunome for sustained growth and value creation.